Stockwatch: Coronavirus And Commercialization
Crisis Profits Unlikely For Pharma And Biotech Firms
Executive Summary
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.